Patent · US Active

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

US10266519B2 · kind B2 · utility

3Cited by

36References

11Claims

0Family size

Assignee

RESPIVERT LTD. · GB

Inventors

Kazuhiro Ito · London, GB
Catherine Elisabeth Charron · London, GB
John King-Underwood · Pendock, GB
Stuart Thomas Onions · Nottingham, GB
Alistair Ian Longshaw · Nottingham, GB
Rudy Laurent Maria Broeckx · Beerse, BE
Walter Ferdinand Maria Filliers · Vremde, BE
Alex Herman Copmans · Beerse, BE

Key dates

Filing date	Nov 14, 2017
Grant date	Apr 23, 2019
Priority date	—
Expiry date	Nov 14, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.